| Neuromyelitis Optica Spectrum Disorder |
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento |
|
|
| Not yet recruiting | 3 | 100 | Europe | satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng | F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 3 | 58 | Europe, Canada, Japan, US, RoW | Ravulizumab, ALXN1210, Ultomiris | Alexion | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | 03/22 | 07/24 | | |
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | 3 | 8 | Europe | Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03330418: A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 3 | 166 | RoW | Placebo, RC18 160 mg | RemeGen Co., Ltd. | Neuromyelitis Optica Spectrum Disorders | 05/25 | 12/25 | | |
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Completed | 3 | 119 | Europe, Canada, Japan, US, RoW | satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder | 05/24 | 05/24 | | |
AQUARELLE, NCT05730699: Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 3 | 105 | RoW | divozilimab, Placebo | Biocad | Neuromyelitis Optica Spectrum Disorders | 09/24 | 04/25 | | |
NCT05314010: A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 3 | 140 | RoW | MIL62, Placebo | Beijing Mabworks Biotech Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 03/25 | 03/27 | | |
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 3 | 8 | Europe, US, RoW | Satralizumab | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder, NMOSD | 03/27 | 09/29 | | |
2019-001829-26: A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Ensayo para evaluar la seguridad y actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante |
|
|
| Not yet recruiting | 2/3 | 15 | Europe | Soliris, Soliris, Concentrate for solution for infusion, Soliris | Alexion Pharmaceuticals Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc. | Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Diseases [C] - Nervous System Diseases [C10] | | | | |
ECU-NMO-303, NCT04155424: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder |
|
|
| Terminated | 2/3 | 5 | Europe, Canada, Japan, US, RoW | Eculizumab, Soliris | Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | 07/23 | 07/23 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Not yet recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
DAWN, NCT05403138: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2/3 | 72 | RoW | Daratumumab, Darzalex, Placebo | Tianjin Medical University General Hospital | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder | 08/24 | 10/24 | | |
| Recruiting | 2/3 | 12 | Europe, Canada, Japan, US, RoW | Ravulizumab, ALXN1210, Ultomiris | Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica Spectrum Disorder | 03/26 | 03/28 | | |
